QDEL vs. CLDX, MYGN, NTLA, VIVO, HSKA, XRAY, MMSI, HAE, NEOG, and ICUI
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Heska (HSKA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Neogen (NEOG), and ICU Medical (ICUI). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation.
Celldex Therapeutics received 165 more outperform votes than QuidelOrtho when rated by MarketBeat users. Likewise, 75.06% of users gave Celldex Therapeutics an outperform vote while only 67.28% of users gave QuidelOrtho an outperform vote.
QuidelOrtho has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
QuidelOrtho has a net margin of -61.65% compared to QuidelOrtho's net margin of -2,385.57%. Celldex Therapeutics' return on equity of 3.96% beat QuidelOrtho's return on equity.
Celldex Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500.
In the previous week, QuidelOrtho had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 15 mentions for QuidelOrtho and 5 mentions for Celldex Therapeutics. QuidelOrtho's average media sentiment score of 0.94 beat Celldex Therapeutics' score of 0.93 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Celldex Therapeutics presently has a consensus target price of $62.17, indicating a potential upside of 39.51%. QuidelOrtho has a consensus target price of $59.00, indicating a potential upside of 51.63%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe QuidelOrtho is more favorable than Celldex Therapeutics.
99.0% of QuidelOrtho shares are held by institutional investors. 3.8% of Celldex Therapeutics shares are held by company insiders. Comparatively, 1.0% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Celldex Therapeutics and QuidelOrtho tied by winning 9 of the 18 factors compared between the two stocks.
Get QuidelOrtho News Delivered to You Automatically
Sign up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
